The Technical Analyst
Select Language :
Context Therapeutics Inc. [CNTX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Context Therapeutics Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Context Therapeutics Inc. is listed at the  Exchange

11.45% $1.382

America/New_York / 27 mar 2024 @ 16:00


Context Therapeutics Inc.: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 22.07 mill
EPS: -1.500
P/E: -0.920
Earnings Date: May 08, 2024
SharesOutstanding: 15.97 mill
Avg Daily Volume: 0.0454 mill
RATING 2024-03-27
B-
Neutral
RATINGS
Rating CashFlow: Buy
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Sell
P/E: Sell
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/a
Ebit
Asset
Debtn/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.920 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.16x
Company: PE -0.920 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$0.905
(-34.51%) $-0.477
Date: 2024-03-28
Expected Trading Range (DAY)

$ 1.277 - 1.483

( +/- 7.46%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-21 Minai-azary Jennifer Lynn Buy 160 115 Stock Option (right to buy)
2024-03-21 Levit Alex C. Buy 153 515 Stock Option (right to buy)
2024-03-21 Lehr Martin A. Buy 291 402 Stock Option (right to buy)
2023-05-31 Kantoff Philip W. Buy 25 000 Stock Option (right to buy)
2023-05-31 West Linda Buy 25 000 Stock Option (right to buy)
INSIDER POWER
100.00
Last 72 transactions
Buy: 4 162 098 | Sell: 2 098 089

Forecast: 16:00 - $1.382

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $1.382
Forecast 2: 16:00 - $1.382
Forecast 3: 16:00 - $1.382
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $1.382 (11.45% )
Volume 0.216 mill
Avg. Vol. 0.0454 mill
% of Avg. Vol 475.27 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Context Therapeutics Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for Context Therapeutics Inc.

RSI

Intraday RSI14 chart for Context Therapeutics Inc.

Last 10 Buy & Sell Signals For CNTX

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Context Therapeutics Inc.

CNTX

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Last 10 Buy Signals

Date Signal @
KAVAUSDMar 28 - 05:24$0.995
BATUSDMar 28 - 05:24$0.337
AVAXUSDMar 28 - 05:25$54.59
CRVUSDMar 28 - 05:24$0.701
IMXUSDMar 28 - 05:23$2.98
FTMUSDMar 28 - 05:22$1.023
ETCUSDMar 28 - 05:22$32.22
SANDUSDMar 28 - 05:21$0.695
EOSUSDMar 28 - 05:21$1.064
PEOPLEUSDMar 28 - 05:190.0396

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.